Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ChIP-Seq for CFI-1 in C. elegans

ABSTRACT: ChIP-Seq for CFI-1 in C. elegans

PROVIDER: PRJNA846739 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19573464.fastq.gz	Fastqsanger.gz
	SRR19573465.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

ChIP-Seq for CFI-1 in C. elegans

Project description:We performed ChIP-seq on endogenously tagged CFI-1::3xFLAG fusion proteins in C. elegans

2022-08-20 | GSE205628 | GEO

C. elegans development (ChIP-Seq)

Project description:C. elegans development (ChIP-Seq)

| PRJNA591185 | ENA

Identification of ChIP-seq and RIME grade antibodies for Estrogen Receptor alpha

Project description:Estrogen Receptor alpha (ERα) is a key driver of most breast cancers, and it is the target of endocrine therapies used in the clinic to treat women with ERα positive (ER+) breast cancer. The two methods ChIP-seq (chromatin immunoprecipitation coupled with deep sequencing) and RIME (Rapid Immunoprecipitation of Endogenous Proteins) have greatly improved our understanding of ERα function during breast cancer progression and in response to anti-estrogens. A critical component of both ChIP-seq and RIME protocols is the antibody that is used to pull down the bait protein. To date, most of the ChIP-seq and RIME experiments for the study of ERα have been performed using the sc-543 antibody from Santa Cruz Biotechnology. However, this antibody has been discontinued, thereby severely impacting the study of ERα in normal physiology as well as diseases such as breast cancer and ovarian cancer. Here, we compare the sc-543 antibody with other commercially available antibodies, and we show that 06-935 (EMD Millipore) and ab3575 (Abcam) antibodies can successfully replace the sc-543 antibody for ChIP-seq and RIME experiments.

2019-03-21 | PXD012930 | Pride

TF ChIP-seq Caenorhabditis elegans (supplemental)

Project description:TF ChIP-seq Caenorhabditis elegans (supplemental)

| PRJNA1177376 | ENA

TF ChIP-seq Caenorhabditis elegans II

Project description:TF ChIP-seq Caenorhabditis elegans II

| PRJNA1169645 | ENA

ChIP-seq for UV-irradiated C. elegans

Project description:ChIP-seq for UV-irradiated C. elegans

| PRJNA563831 | ENA

ChIP-seq Drosophila melanogaster and Caenorhabditis elegans

Project description:ChIP-seq Drosophila melanogaster and Caenorhabditis elegans

| PRJNA1177430 | ENA

ChIP-Seq of UNC-3 in C. elegans

Project description:We performed ChIP-seq on endogenously tagged UNC-3::GFP fusion proteins in C. elegans

2020-10-01 | GSE143165 | GEO

mRNA-Seq analysis of cSCC cells followed by siRNA-induced gene knockdown of CFI.

Project description:Keratinocyte carcinomas (BCC and cSCC) are the most common cancers worldwide. cSCC is considered as the most prevalent metastatic skin malignancy and its incidence is increasing globally. The complement system is a fundamental part of the host immune defense. It is composed of three distinct pathways (classical, alternative and lectin) that get activated sequentially. However, the process of complement activation is rigorously regulated by a series of soluble and membrane-bound inhibitor proteins that protect the host cells from lytic damage. One of these soluble negative regulators is complement factor I (CFI) which is an 88 kDa serine protease that hampers all three complement pathways through blockade of C3- and C5- convertases by cleaving C3b and C4b. Oligonucleotide array (Affymetrix)-based analysis of normal human epidermal keratinocytes (NHEKs; n=5), primary (Prim. cSCC; n=5) and metastatic (Met. cSCC; n=3) cSCC cell lines as well as next-generation-sequencing (SOLiD) based transcriptome profiling of NHEKs (n=4), primary (Prim. cSCC; n=5) and metastatic (Met. cSCC; n=3) cSCC cell lines revealed marked overexpression of CFI in cSCC cells compared to NHEKs (GSE66368 and GSE66412 respectively). Furthermore, we have previously shown that knockdown of CFI inhibits proliferation and migration of cSCC cells and potently impedes growth of cSCC xenograft tumors in vivo. In these respects, we intended to further investigate the functional role and molecular mechanism of CFI in cSCC progression via analyzing the mRNA expression profile of CFI in cSCC cells.

2021-05-19 | GSE166421 | GEO

ChIP-Seq of UNC-3 in C. elegans

Project description:ChIP-Seq of UNC-3 in C. elegans

| PRJNA599134 | ENA